Neurona Therapeutics’ Post

View organization page for Neurona Therapeutics, graphic

5,436 followers

If you are attending the Jefferies Global Healthcare Conference in New York City this week, our CEO, Cory R. Nicholas, PhD, will be hosting meetings to update investors on the most recent data from Neurona's ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-resistant, unilateral mesial temporal lobe epilepsy (MTLE) and the Company's plans to develop its pipeline of allogeneic, off-the-shelf, regenerative neural cell therapy products. #epilepsy #celltherapy

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics